Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of Intravenous BIIB093 (glibenclamide) in Patients With Brain Contusion
2018-003858-24Phase 2Terminated
- Sponsor
- Biogen
- Start
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in cerebral contusion comparing BIIB093 (glibenclamide) IV with Placebo IV (2 arms). Primary endpoint: Proportion of Participants With Contusion Expansion. Started Jun 2019; status: terminated.
02
Drugs
glibenclamide
03
Conditions
cerebral contusion
Beyond the preview
Go deeper on 2018-003858-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003858-24.